Roche, Upsher-Smith in deal for molecule inhibitor; Array BioPharma to collaborate with Pierre Fabre;

> Roche ($RHHBY) and Upsher-Smith Laboratories have reached a global agreement to develop an oral small molecule inhibitor of Vascular Adhesion Protein for the treatment of inflammatory diseases. Article

> Array BioPharma ($ARRY) and Pierre Fabre announced a deal to collaborate on the global development of Array's late-stage oncology products, binimetinib and encorafenib. Article

>The FDA has awarded a $4.9 million grant to Rutgers University's Engineering Research Center to speed up pill creation through continuous manufacturing. Article

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.